BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Schering AG submitted on 20 December 2001 an application for Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) through the 
centralised procedure for Ventavis, which was designated as an orphan medicinal product 
EU/3/00/014 on 29 December 2000.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr E. Abadie 
Co-Rapporteur:  Prof S. Garattini 
Orphan Drugs: 
Iloprost was designated as an orphan medicinal product in the following indication: “Treatment of 
primary and of the following forms of secondary pulmonary hypertension: connective tissue disease 
pulmonary hypertension, drug-induced pulmonary hypertension, portopulmonary hypertension, 
pulmonary hypertension associated with congenital heart disease, chronic thromboembolic pulmonary 
hypertension.” 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  17  September  1998.  The  Scientific 
Advice pertained to part III and part IV of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 28 January 2002. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
15 April 2002.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 10 April 2002. 
During  the  meeting  on  28  –  30  May  2002  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 30 May 2002. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
12 November 2002. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 6 January 2003. 
During  the  CPMP  meeting  on  21  –  23  January  2003  the  CPMP  adopted  a  list  of  outstanding 
issues to be addressed by the applicant in writing and if  necessary during an oral explanation. 
The list of outstanding issues was sent to the applicant on 24 January 2003. 
The applicant provided  written information on these  outstanding issues to all CPMP members 
on 27 February 2003.  
The  Rapporteur/Co-Rapporteurs’  joint  review  on  the  applicant’s  responses  to  the  list  of 
outstanding issues was circulated to all CPMP members on 11 March 2003.  
1/2 

EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
During  the  CPMP  meeting  on  18  –  19  March  2003  the  CPMP  adopted  a  list  of  outstanding 
issues  to  be  addressed  by  the  applicant  in  writing  and  during  an  oral  explanation.  The  list  of 
outstanding issues was sent to the applicant on 19 March 2003. 
The applicant provided  written information on these  outstanding issues to all CPMP members 
on 3 April 2003.   
The Rapporteur/Co-Rapporteurs’ joint review on the responses to the list of outstanding issues 
was circulated to all CPMP members on 14 April 2003. 
During  the  CPMP  meeting  on  23  –  25  April  2003,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP on 24 April 2003. 
During the meeting on 20 – 22 May 2003 the CPMP, in the light of the overall data submitted 
and the scientific discussion within the Committee, issued a positive opinion for granting a 
Marketing Authorisation under exceptional circumstances to Ventavis on 22 May 2003.  
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 16 September 2003. 
2/2 

EMEA 2004 
 
 
 
 
